{"classes":[{"categories":[{"measurements":[{"comment":"The upper bound of the 95% CI has not been reached.","groupId":"OG000","lowerLimit":"59.9","upperLimit":"NA","value":"73.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Monitored using the method of Thall et al. Estimated using the Kaplan-Meier method. Log-rank test will be performed to test the difference in time-to-event distributions between patient groups. Cox proportional hazards model will be used to include multiple covariates in the time-to-event analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Beginning 60-180 days post-transplant, participants receive ixazomib citrate PO on days 1, 8, and 15 and lenalidomide PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLenalidomide: Given PO\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Treatment (Ixazomib Citrate, Lenalidomide)"}],"paramType":"MEDIAN","populationDescription":"The upper bound of the 95% CI has not been reached.","reportingStatus":"POSTED","timeFrame":"Time from autologous stem cell transplant (ASCT) to time of clinical progression or death or the time of last contact, assessed up to 30 days after completion of study treatment","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"Months"}